随着AIM市场的下滑,BAY顾问正在以3.5亿英镑获得联盟药厂。 BAY Advisors is acquiring Alliance Pharma for £350 million as the AIM market faces decline.

专业药品公司Alliance Pharma正在由其最大股东,BAY Advisors以3.5亿英的价格私有化. Specialty drugs company Alliance Pharma is being taken private by its largest shareholder, BAY Advisors, for £350 million. 随着AIM市场争斗、面临高成本、官僚主义和流动性低,导致公司大量损失,这一举动随之而来。 The move comes as the AIM market struggles, facing high costs, bureaucracy, and low liquidity, leading to a significant loss of companies. 政策制定者和行业领导人敦促采取紧急行动, 保持AIM在创新和企业的相关性. Policymakers and industry leaders urge urgent action to maintain AIM's relevance for innovation and enterprise.